Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials.
Syeda Kanza Kazmi, Muhammad Abdul Rehman, Hanaa Tariq et al.
✦ AI-curated · Sources linked
In 30 seconds
This reconstructed individual patient-data meta-analysis of 18 randomized controlled trials examined survival outcomes across targeted treatment classes in BRAF V600E-mutant metastatic colorectal cancer. Across first-line studies, pooled median overall survival was 22.3 months with BRAF-directed regimens, 17.1 months with VEGF-targeted therapy, and 10.1 months with EGFR-directed therapy. Compared with EGFR inhibition, BRAF-directed regimens were associated with improved overall survival (HR 0.43, 95% CI 0.31-0.60; P < 0.001) and progression-free survival (HR 0.47, 95% CI 0.42-0.53; P < 0.001).
Key findings
- First-line BRAF-directed regimens had pooled median overall survival of 22.3 months, versus 17.1 months for VEGF-targeted and 10.1 months for EGFR-directed therapy.
- Compared with EGFR inhibition, BRAF-directed regimens were associated with improved overall survival (HR 0.43, 95% CI 0.31-0.60; P < 0.001).
- BRAF-directed regimens were associated with improved progression-free survival versus EGFR inhibition (HR 0.47, 95% CI 0.42-0.53; P < 0.001).
- VEGF inhibition was also associated with better overall survival than EGFR inhibition (HR 0.56, 95% CI 0.38-0.81; p < 0.001).
Why it matters
The analysis compares survival outcomes across targeted therapeutic classes in an aggressive molecular subtype for which the abstract describes limited response to conventional chemotherapy. Its findings suggest that outcomes differ across pathway-targeted approaches, with BRAF-directed regimens associated with the most favourable survival and EGFR-directed regimens with the poorest outcomes in the analyses reported.
What to keep in mind
Individual patient data were reconstructed from digitized Kaplan-Meier curves rather than obtained directly from trial participants; the analysis also compares results across studies and treatment classes.